Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ARIAD PHARMACEUTICALS INC (ARIA)
|
Add to portfolio |
|
|
|
| Price: |
$23.95
| | Metrics |
| OS: |
194.2
|
M
| |
|
|
| Market cap: |
$4.65
|
B
| |
-1
|
% ROIC
|
|
Net debt:
|
$238
|
M
| |
13.3
|
x Debt/EBITDA
|
|
EV:
|
$4.89
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$18.0
|
M
| |
272.2
|
x EV/EBITDA
|
|
EBIT
|
($911.0)
|
k
| |
|
|
| EPS |
($0.18)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| Revenues | 118.8 | 105.4 | 45.6 | 0.6 | 25.3 | 179.0 | 8.3 | 7.1 |
| Revenue growth | 12.7% | 131.4% | 8065.1% | -97.8% | -85.9% | 2055.9% | 17.2% | -82.1% |
| Cost of goods sold | 2.1 | 5.2 | 9.6 | 0.0 | 0.0 | 0.1 | 0.1 | 78.9 |
| Gross profit | 116.7 | 100.2 | 35.9 | 0.6 | 25.3 | 178.8 | 8.2 | -71.9 |
| Gross margin | 98.2% | 95.0% | 78.9% | 100.0% | 100.0% | 99.9% | 98.3% | -1014.6% |
| Selling, general and administrative | 162.8 | 139.8 | 146.6 | 60.9 | 24.4 | | | |
| Research and development | 171.2 | 120.6 | 162.9 | 144.7 | 77.7 | 58.0 | 63.4 | |
| General and administrative | | | | | | 16.1 | 16.9 | 28.1 |
| EBITA | -217.2 | -160.2 | -273.5 | -204.8 | -75.1 | 105.8 | -71.0 | -71.9 |
| EBITA margin | -182.9% | -151.9% | -600.4% | -36710.0% | -296.9% | 59.1% | -855.6% | -1014.6% |
| Amortization of intangibles | 0.0 | 0.0 | 0.0 | 0.2 | 1.7 | 0.9 | 1.0 | |
| EBIT | -217.3 | -160.2 | -273.6 | -205.1 | -76.8 | 104.9 | -72.0 | -71.9 |
| EBIT margin | -182.9% | -152.0% | -600.4% | -36749.1% | -303.6% | 58.6% | -867.7% | -1014.6% |
| Pre-tax income | -234.6 | -162.0 | -273.7 | -220.9 | -123.6 | 85.2 | -80.0 | 0.0 |
| Income taxes | -3.4 | 0.6 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 1.4% | | | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net income | -231.2 | -162.6 | -274.2 | -220.9 | -123.6 | 85.2 | -80.0 | 0.0 |
| Net margin | -194.6% | -154.3% | -601.7% | -39582.8% | -488.5% | 47.6% | -963.7% | 0.0% |
| |
| Diluted EPS | ($1.23) | ($0.87) | ($1.49) | ($1.34) | ($0.93) | $0.74 | ($0.86) | $0.00 |
| Shares outstanding (diluted) | 188.7 | 186.8 | 183.6 | 165.0 | 132.4 | 114.7 | 93.3 | 69.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|